2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2640

Can GP88 (Progranulin) be Used to Predict the Efficacy of Infliximab?
Abstract Number: 1272

Can Histologically Defined Peri-Articular Vascular Channels be Identified on High-Resolution Computed Tomography? – a Study in Cadaveric Finger Joints
Abstract Number: 352

Can Lumbar Spine Bone Mineral Density Predict Readmission in Denosumab-Treated Chronic Kidney Disease Patients?
Abstract Number: 1885

Can Nailfold Videocapillaroscopy Images be Interpreted Reliably By Different Observers? Results of an Inter-Reader and Intra-Reader Exercise Among Rheumatologists with Different Experience in This Field
Abstract Number: 1133

Can Patient Videos in Lectures Increase Interest and Improve Learning in Rheumatology Among Second Year Medical Students?
Abstract Number: 1299

Can the 3D-Modified Dixon Methods Replace the Conventional Sacroiliac Joint Magnetic Resonance Imaging?
Abstract Number: 500

Can Thiol/Disulphide Is a Novel Marker in Rheumatoid Arthritis?
Abstract Number: 782

Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review
Abstract Number: 1735

Canadian Humira Post-Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA): Interim Analysis
Abstract Number: 614

Canadian Study of Outcomes in Adalimumab (HUMIRA®) Patients with Support for Adherence – Results from the Companion Study
Abstract Number: 2381

Canakinumab Monotherapy for the Treatment of Majeed Syndrome. Five-Year Experience
Abstract Number: 2990

Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort
Abstract Number: 2327

Cardiac Involvement in Inflammatory Myopathies: A Report from the Remicam Registry
Abstract Number: 1792

Cardiac Surgery in Systemic Lupus Erythematosus Patients: Clinical Characteristics and Outcomes
Abstract Number: 2097

Cardiolipin-Producing Candidate Commensals in the Gut Microbiome of Antiphospholipid Syndrome Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].